Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2006-05-23
2006-05-23
Brusca, John (Department: 1631)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C435S005000, C435S006120, C424S094600, C424S185100, C424S186100, C424S226100, C530S300000, C530S350000, C536S023100, C536S024100, C514S04400A
Reexamination Certificate
active
07048931
ABSTRACT:
Compositions and methods for the therapy and diagnosis of cancer, such as prostate cancer, are disclosed. Compositions may comprise one or more prostate-specific proteins, immunogenic portions thereof, or polynucleotides that encode such portions. Alternatively, a therapeutic composition may comprise an antigen presenting cell that expresses a prostate-specific protein, or a T cell that is specific for cells expressing such a protein. Such compositions may be used, for example, for the prevention and treatment of diseases such as prostate cancer. Diagnostic methods based on detecting a prostate-specific protein, or mRNA encoding such a protein, in a sample are also provided.
REFERENCES:
patent: 4818707 (1989-04-01), Breneman
patent: 5776468 (1998-07-01), Hauser et al.
patent: 5786148 (1998-07-01), Bandman et al.
patent: 5846532 (1998-12-01), Kline
patent: 6090611 (2000-07-01), Covacci et al.
patent: 6107090 (2000-08-01), Bander
patent: 6130043 (2000-10-01), Billing-Medel et al.
patent: 6136311 (2000-10-01), Bander
patent: 6252047 (2001-06-01), Billing-Medel et al.
patent: 6261562 (2001-07-01), Xu et al.
patent: 6262245 (2001-07-01), Xu et al.
patent: 6350452 (2002-02-01), Riss
patent: 6375952 (2002-04-01), Koelle et al.
patent: 6620922 (2003-09-01), Xu et al.
patent: 2002/0086301 (2002-07-01), Billing-Medel et al.
patent: 317 141 (1989-05-01), None
patent: 652 014 (1995-05-01), None
patent: 679 716 (1995-11-01), None
patent: WO 93/14755 (1993-08-01), None
patent: WO 93/25224 (1993-12-01), None
patent: WO 94/09820 (1994-05-01), None
patent: WO 95/04548 (1995-02-01), None
patent: WO 95/14772 (1995-06-01), None
patent: WO 95/30758 (1995-11-01), None
patent: WO 96/21671 (1996-07-01), None
patent: WO 97/33909 (1997-09-01), None
patent: WO 98/12302 (1998-03-01), None
patent: WO 98/17687 (1998-04-01), None
patent: WO 98/20117 (1998-05-01), None
patent: WO 98/31799 (1998-07-01), None
patent: WO 98/37093 (1998-08-01), None
patent: WO 98/38310 (1998-09-01), None
patent: WO 98/39446 (1998-09-01), None
patent: WO 98/45435 (1998-10-01), None
patent: WO 98/50567 (1998-11-01), None
patent: WO 99/06548 (1999-02-01), None
patent: WO 99/06550 (1999-02-01), None
patent: WO 99/06552 (1999-02-01), None
patent: WO 99/25825 (1999-05-01), None
patent: WO 99/31236 (1999-06-01), None
patent: WO 99/67384 (1999-12-01), None
patent: WO 00/04149 (2000-01-01), None
patent: WO 01/25272 (2001-04-01), None
patent: WO 01/34629 (2001-05-01), None
patent: WO 01/34802 (2001-05-01), None
patent: WO 01/51633 (2001-07-01), None
patent: WO 01/81577 (2001-11-01), None
Stedman, T.L., Stedman's Medical Dictionary, 22nd Edition, The Williams & Williams Company, Baltimore, 1972. See pp. 37 and 952.
Gygi et al., Molecular and Cellular Biology, vol. 19, pp. 1720-1730, 1999.
Anderson et al., Electrophoresis, vol. 18, pp. 533-537, 1997.
Ezzell, C., The J. NIH Research, vol. 7, pp. 46-49. 1995.
Aspinall et al., Journal of Urology, vol. 154, pp. 622-628, 1996.
Chen et al., Nature, vol. 407, pp. 916-920, 2000.
Kajimoto et al., J. Biochem. vol. 112, pp. 28-32, 1993.
Abbas et al., Cellular and Molecular Immunology, Published by W.B. Saunders Company, 1991. See pp. 50-52.
Xu et al., WO 98/37418-A2, Aug. 27, 1998.
Ahn and Kunkel, “The structural and functional diversity of dystrophin,”Nature Genetics 3: 283-291, Apr. 1993.
Alexeyev et al., “Improved antibiotic-resistance gene cassettes and omega elements forEscherichia colivector construction and in vitro deletion/insertion mutagenesis,”Gene 160:63-67, 1995.
Anderson, W. F., “Human gene therapy,”Nature 392(Suppl.): 25-30, Apr. 30, 1998.
Berthon et al., “Predisposing gene for early-onset prostate cancer, localized on chromosome 1q42.2-43,”Am. J. Hum. Genet. 62(6):1416-1424, Jun. 1998.
Blok et al., “Isolation of cDNA that are differentially expressed between androgen-dependent and androgen-independent prostate carcinoma cells using differential display PCR,”The Prostate 26:213-224, 1995.
Bowie et al., “Deciphering the Message in Protein Sequences: Tolerance to Amino Acid Substitutions,”Science 247:1306-10, Mar. 16, 1990.
Busselmakers et al., Genbank Accession No. AF103907, Aug. 14, 2000.
Busselmakers et al., Genbank Accession No. AF103908, Aug. 14, 2000.
Cawthon et al., “cDNA sequence and genomic structure of EVI2B, a gene lying within an intron of the neurofibromatosis type 1 gene,”Genomics 9:446-460, 1991.
Chu et al., “CpG oligodeoxynucleotides act as adjuvants that switch on T helper 1 (Th1) immunity,”J. Exp. Med. 186(10): 1623-1631, Nov. 17, 1997.
Coleman et al.,Fundamental Immunology, Wm. C. Brown Publishers, Dubuque, Iowa, 1989, pp. 465-466.
Database EMBL Accesion No. AA453562, Jun. 5, 1997, Hillier et al., “Homo sapienscDNA clone 788180.”
Derwent Geneseq Database, Accession No. AAV58522, Dec. 8 1998.
Derwent Geneseq Database, Accession No. AAV61287, Jan. 6, 1999.
Duerst and Nees, “Nucleic acid characteristic of late or early passage cells immortalized by papilloma virus-and related polypeptide(s) and antibodies, used for diagnosis and treatment of cervical cancer and assessing potential for progression of cervical lesions,” Derwent World Patent Index, Accession No. 1998-121623, 1998. See also German Patent DE 19649207 C1.
El-Shirbiny, “Prostatic Specific Antigen,”Advances In Clinical Chemistry 31:99-133, 1994.
Fannon, M.R., “Gene expression in normal disease states—identification of therapeutic targets,”Trends in Biotechnology 14: 294-298, Aug. 1996.
Gao et al., “Blinded Evaluation of Reverse Transcriptase-Polymerase Chain Reaction Prostate-Specific Antigen Peripheral Blood Assay for Molecular Staging of Prostate Cancer,”Urology 53:714-721, 1999.
Garde, S.V. et al., “Prostate inhibin peptide (PIP) in prostate cancer: a comparative immunohistochemical study with prostate-specific antigen (PSA) and prostatic acid phosphatase (PAP),”Cancer Letters 78: 11-17, 1994.
GenBank Accession No. AF047020, Feb, 1, 1999.
GenBank Database, Accession No. AA112574, May 29, 2003.
Hara et al., “Characterization of cell phenotype by a novel cDNA library subtraction system: expression of CD8α in a mast cell-derived interleukin-4-dependent cell line,”Blood 84(1):189-199, Jul. 1, 1994.
Harris et al., “Polycystic Kidney Disease 1: identification and analysis of the primary defect,”J. Am. Soc. of Nephrol. 6:1125-1133, 1995.
Hillier et al., Genbank Accession No. AA100799, Dec. 23, 1997.
Hillier et al., Genbank Accession No. R20590, Apr. 18, 1995.
Hudson, T., Genbank Accession No. G22461, May 31, 1996.
Kool, M. et al., “Analysis of Expression ofcMoat(MRP2),MRP3, MRP4,andMRP5,Homologues of the multidrug resistance-associated protein gene (MRP1) in human cancer cell lines,”Cancer Research 57:3537-3547, Aug. 15, 1997.
Kroger, B. “New serine protease form human prostate, useful for identifying specific inhibitors, antibodies and probes,” Derwent World Patent Index, Accession No. 99-432218, 1999. See also European Patent EP 936 270 A2.
Lalvani et al., “Rapid effector function in CD8+memory T cells ,”J. Exp. Med. 186(6):859-865, Sep. 15, 1997.
Lee, K. et al., “Isolation of Moat-B, a widely expressed multidrug resistance-associated protein/canalicular multispecific organic anion transporter-relatred transporter”Cancer Research 58: 2741-2747, Jul. 1, 1998.
Murphy, G. et al., “Comparison of Prostate Specific Membrane Antigen, and Prostate Specific Antigen Levels in Prostatic Cancer Patients,”Anticancer Research 15: 1473-1480, 1995.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551449, Sep. 5, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA551759, Aug. 11, 1997.
National Cancer Institute, Cancer Genome Anatomy Project (NCI-CGAP), Genbank Accession No. AA631143, Oct. 31, 1997.
National Cancer Institute, Cancer Ge
Day Craig H.
Dillon Davin C.
Harlocker Susan L.
Jiang Yuqiu
Kalos Michael D.
Brusca John
Corixa Corporation
Seed IP Law Group PLLC
Zhou Shubo (Joe)
LandOfFree
Compositions and methods for the therapy and diagnosis of... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Compositions and methods for the therapy and diagnosis of..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Compositions and methods for the therapy and diagnosis of... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3641436